Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Replimune Group Inc
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 22, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 16, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 12, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 21, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 08, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Pricing of Upsized Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Proposed Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
November 21, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 30, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
